Clinical trials: Influenza Immunisation
Influenza, Influenza Immunisation
Age and Response to Flu Vaccines
The study will be designed as a prospective surveillance of the immune response to seasonal influenza vaccination in 240 healthy children and adults ages 9 and over.
- Trial name
- NCT03328325
- Testing
- Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Immunisation
Flublok or Fluzone With Advax-CpG55.2 or AF03
This is a Phase I, randomized, double blinded, clinical trial in up to 240 males and non-pregnant females, 18-45 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03945825
- Testing
- AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- 8 sites in United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Avian Influenza, Influenza Immunisation
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
This is a randomized, double-blinded, Phase II study in healthy males and non-pregnant females 19 years and older that is designed to assess the safety, reactogenicity, and immunogenicity of a pre-pandemic 2017 monovalent…
- Trial name
- NCT03312231
- Testing
- AS03, Inactivated influenza H7N9 vaccine, Phosphate Buffered Saline (PBS) diluent
- Where
- 5 sites in United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Immunisation
Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers
This was an open label, single arm, Phase IV study of longitudinal immunologic responses to influenza vaccine in healthy adult participants, with the aim of enrolling up to 70 participants.
- Trial name
- NCT02385123
- Testing
- Influenza Virus Vaccine Inactivated
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Immunisation
Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination
This was a Phase IV open label and single arm study, with the aim of enrolling up to 55 healthy males and non-pregnant females in a single site, age 18-49 years old, inclusive.
- Trial name
- NCT02485639
- Testing
- Influenza Virus Vaccine Inactivated
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Safety, Adverse Event Following Immunisation
Safety of RIV4 Versus IIV4 in Pregnant Women
This is a prospective, randomized clinical trial. During the study, pregnant women will be randomized (1:1) to receive RIV4 or IIV4. Vaccines will be administered by licensed providers.
- Conditions
- Safety, Adverse Event Following Immunisation, Birth Outcomes
- Trial name
- NCT03969641
- Testing
- Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Duke University
Influenza, Influenza Immunisation
Development of Childhood Anti-Influenza Immunity
This study is a prospective surveillance of the immune response to seasonal vaccination in healthy children. The study will enroll a total of approximately 220 subjects.
- Trial name
- NCT03673345
- Testing
- Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Immunisation
H3N2 M2SR in Pediatric Population
This is a Phase I double-blind, randomized, placebo-controlled study in 50 healthy adolescents and children, 9-17 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03553940
- Testing
- Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine, Quadrivalent MDCK Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Avian Influenza, Influenza Immunisation
2013/2017 H7N9 Prime-Boost Interval
This is a trial designed to assess the safety, reactogenicity and immunogenicity of one or two doses of monovalent inactivated split influenza 2013 and 2017 A/H7N9 virus vaccines administered intramuscularly at different dosages…
- Trial name
- NCT03589807
- Testing
- A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
- Where
- 6 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Avian Influenza, Influenza Immunisation
2017 A/H7N9 IIV Revaccination
This is a Phase II clinical trial in up to 420 males and non-pregnant females, 19 to 70 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03738241
- Testing
- A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent
- Where
- 9 sites in United States
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Avian Influenza, Influenza Immunisation
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
This is a randomized, double-blinded, Phase II study in healthy males and non-pregnant females, 18-64 years of age. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of a pre-pandemic 2017…
- Trial name
- NCT03682120
- Testing
- A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent
- Where
- 7 sites in United States
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Avian Influenza, Influenza
Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4
This is a randomized, un-blinded, Phase II study in males and non-pregnant females, who are in good health, 19 to 64 years of age.
- Conditions
- Avian Influenza, Influenza, Influenza Immunisation
- Trial name
- NCT03318315
- Testing
- AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- 4 sites in United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Immunisation
Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine
This is a Phase II randomized, double-blind, placebo-controlled trial in 120 males and non-pregnant females, 18 to 49 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03058692
- Testing
- Influenza Multimeric-001 Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)